Open access
Open access
Powered by Google Translator Translator

Allergy & Immunology

Moderna released more Covid-19 vaccine results. They’re very encouraging.

1 Dec, 2020 | 08:15h | UTC

Moderna released more Covid-19 vaccine results. They’re very encouraging. – Vox

News release: Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization

Commentaries: ‘Absolutely remarkable’: No one who got Moderna’s vaccine in trial developed severe COVID-19 – Science AND Moderna to submit Covid-19 vaccine to FDA as full results show 94% efficacy – STAT AND More Good News For Moderna’s COVID-19 Vaccine Candidate – NPR AND Moderna to seek emergency authorization for COVID-19 vaccine – CIDRAP

 

Commentary on Twitter

 

Opinion: Pfizer and Moderna’s “95% effective” vaccines—let’s be cautious and first see the full data

1 Dec, 2020 | 08:13h | UTC

Peter Doshi: Pfizer and Moderna’s “95% effective” vaccines—let’s be cautious and first see the full data – BMJ Opinion

 

CDC Study showing decline in SARS-CoV-2 antibodies after infection suggests antibody surveys underestimate infections

26 Nov, 2020 | 09:08h | UTC

Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network — 12 States, April–August 2020 – CDC Morbidity and Mortality Weekly Report

Commentary: COVID-19 antibody surveys underestimate infections: study – MedicalXpress

 

Commentary on Twitter (Thread – Click for more)

 

Opinion: “The AstraZeneca Covid Vaccine Data Isn’t Up to Snuff”

26 Nov, 2020 | 09:02h | UTC

The AstraZeneca Covid Vaccine Data Isn’t Up to Snuff – Wired

Commentaries: A timeline of the oxford-Astrazeneca Covid-19 vaccine trials – by Hilda Bastian AND After Admitting Mistake, AstraZeneca Faces Difficult Questions About Its Vaccine – The New York Times AND AstraZeneca manufacturing error clouds vaccine study results – Associated Press

 

Randomized trial: Convalescent Plasma does not improve clinical status or overall mortality in severe Covid-19 pneumonia

25 Nov, 2020 | 09:17h | UTC

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia – New England Journal of Medicine

Commentary: New trial of convalescent plasma for covid-19 falls flat, another setback for hyped treatment – Brief19

 

Commentary on Twitter

 

With more data on its COVID-19 vaccine, Russian institute offers new evidence of success

25 Nov, 2020 | 09:13h | UTC

With more data on its COVID-19 vaccine, Russian institute offers new evidence of success – Science

News release: SECOND interim analysis of clinical trial data showed a 91.4% efficacy for the Sputnik V vaccine on day 28 after the first dose; vaccine efficacy is over 95% 42 days after the first dose – Sputnik V

Commentaries: Expert reaction to press release reporting the second interim analysis of the efficacy of the Sputnik V vaccine – Science Media Centre AND Russia says Sputnik V virus vaccine 95% effective – MedicalXpress

 

Why the AstraZeneca-Oxford Covid-19 vaccine is different. It does not require extremely cold temperatures for storage, and the price will be “a fraction” of the expense of the other vaccine candidates

24 Nov, 2020 | 09:32h | UTC

Why the AstraZeneca-Oxford Covid-19 vaccine is different – Vox

 

Why does the AstraZeneca-Oxford COVID-19 vaccine’s efficacy vary so much? Here’s what we know

24 Nov, 2020 | 09:30h | UTC

Why Does the AstraZeneca COVID-19 Vaccine’s Efficacy Vary So Much? Here’s What We Know – TIME

Related: Why Oxford’s positive COVID vaccine results are puzzling scientists – Nature

 

Emergency COVID-vaccine approvals pose a dilemma for scientists. It could complicate efforts to study long-term outcomes, such as safety, how long protection lasts and whether the jab prevents infection or just the disease

24 Nov, 2020 | 09:28h | UTC

Why emergency COVID-vaccine approvals pose a dilemma for scientists – Nature

 

Covid-19: Oxford University vaccine shows 70% protection

23 Nov, 2020 | 09:54h | UTC

Covid-19: Oxford University vaccine shows 70% protection – BBC

News release: Oxford University breakthrough on global COVID-19 vaccine

 

Commentary on Twitter

 

Phase 2 trial of Oxford COVID-19 vaccine finds it is safe and provokes immune response in young as well as in older adults

20 Nov, 2020 | 08:50h | UTC

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Commentaries: Covid: Oxford vaccine shows ‘encouraging’ immune response in older adults – BBC AND Age and frailty in COVID-19 vaccine development – The Lancet AND Expert reaction to phase 2 trial safety and immunogenicity data from the Oxford COVID-19 vaccine trial including in healthy older adults – Science Media Centre AND Phase 2 trial of Oxford COVID-19 vaccine in healthy older adults finds it is safe and provokes immune response – The Lancet

 

Commentary on Twitter

 

Pfizer and BioNTech to submit Covid-19 vaccine data to FDA as full results show 95% efficacy

19 Nov, 2020 | 09:36h | UTC

Pfizer and BioNTech to submit Covid-19 vaccine data to FDA as full results show 95% efficacy – STAT

News release: Pfizer and Biontech conclude phase 3 study of Covid-19 vaccine candidate, meeting all primary efficacy endpoints

Commentaries: ‘Incredible milestone for science.’ Pfizer and BioNTech update their promising COVID-19 vaccine result – Science AND Pfizer: COVID-19 shot 95% effective, seeking clearance soon – Associated Press AND Expert reaction to announcement by Pfizer that they have concluded the Phase III study of their COVID-19 vaccine candidate after demonstrating 95% efficacy – Science Media Centre AND Covid vaccine: Pfizer says ‘94% effective in over-65s’ – BBC

 

Opinion: For billion-dollar COVID vaccines, basic government-funded science laid the groundwork

19 Nov, 2020 | 09:33h | UTC

For Billion-Dollar COVID Vaccines, Basic Government-Funded Science Laid the Groundwork – Scientific American

 

[Preprint] Study suggests immunity to the Coronavirus may last years

18 Nov, 2020 | 09:20h | UTC

Immunological memory to SARS-CoV-2 assessed for greater than six months after infection – bioRxiv

Commentaries: Immunity to the Coronavirus May Last Years, New Data Hint – New York Times AND Could coronavirus immunity last YEARS? Study finds even survivors who had mild COVID-19 are protected for at least 8 months and their immune ‘memory’ may last MUCH longer – Daily Mail AND COVID-19: Study Suggests Durable Immune Response After SARS-CoV-2 Infection – NEJM Journal Watch

 

Commentary from the author on Twitter (thread – click for more)

 

Chinese Covid-19 vaccine candidate (CoronaVac) appears safe and induces an immune response in healthy volunteers in phase 1/2 clinical trial

18 Nov, 2020 | 09:19h | UTC

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial – The Lancet

Commentaries: Covid-19: Chinese vaccine ‘successful in mid-stage trials’ – BBC AND Expecting the unexpected with COVID-19 vaccines – The Lancet Infectious Diseases

 

Commentary on Twitter

 

[Press release – not published yet] Moderna’s COVID-19 vaccine candidate shows 94.5% protection in an interim analysis of the phase 3 COVE study

17 Nov, 2020 | 09:55h | UTC

Press release: Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study

See also: Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures

Commentaries: What Moderna’s Covid-19 vaccine results mean for ending the pandemic – Vox AND Moderna follows Pfizer with exciting vaccine news – how to read these dramatic developments – The Conversation AND Moderna’s COVID Vaccine Is  95% Effective – Independent NIH-Appointed Board Assessment – Higher Storage Temperature Make It Even Better News – Health Policy Watch AND Moderna’s Vaccine News “Encouraging” But Won’t Solve Immediate Problem of Virus Surge in Europe & Americas – WHO – Health Policy Watch AND COVID vaccine excitement builds as Moderna reports third positive result – Nature AND Moderna’s Covid-19 vaccine is strongly effective, early look at data show – STAT AND With strong data on two Covid-19 vaccines, we have more answers about the road ahead — and questions too – STAT AND Early data show Moderna’s COVID vaccine 94.5% effective – CIDRAP AND A Note Of Caution On Moderna’s Promising Covid-19 Vaccine News – Forbes AND Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine – NIH News Releases AND Moderna: Covid vaccine shows nearly 95% protection – BBC AND Latest vaccine success is good news but high price may restrict access – The Guardian AND ‘Just beautiful’—Another COVID-19 vaccine, from newcomer Moderna, succeeds in large-scale trial – Science AND Moderna trial success gives world more hope in race to end pandemic – Reuters AND Expert reaction to Moderna announcement of its phase 3 vaccine interim results – Science Media Centre

 

Opinion: “Why the Pfizer and BioNTech vaccine is a cause for optimism — and skepticism. Vaccine science by press release has to stop”

11 Nov, 2020 | 09:25h | UTC

Why the Pfizer and BioNTech vaccine is a cause for optimism — and skepticism – Vox

Related commentaries: Champagne and questions greet first data showing that a COVID-19 vaccine works – Science AND 90% efficacy for Pfizer’s COVID-19 mRNA vaccine is striking. But we need to wait for the full data – The Conversation

See also: Science by press release: When the story gets ahead of the science – CNN

 

Podcast on chronic cough. Don’t be afraid to try empiric therapies! PPIs for GERD, antihistamines and intranasal steroids for post-nasal drip, and inhaled corticosteroids for post-viral cough are generally low-risk and will treat many cases.

11 Nov, 2020 | 09:04h | UTC

#241 Chronic Cough – The Curbsiders Internal Medicine Podcast

 

News Release [Not Published Yet]: Vaccine candidate 90% effective against Covid-19 according to manufacturer

10 Nov, 2020 | 09:41h | UTC

News Release: Pfizer and Biontech announce vaccine candidate against Covid-19 achieved success in first interim analysis from phase 3 study

Commentaries: What Pfizer’s landmark COVID vaccine results mean for the pandemic – Nature AND Covid-19: Vaccine candidate may be more than 90% effective, interim results indicate – The BMJ AND Covid vaccine: First ‘milestone’ vaccine offers 90% protection – BBC AND Hopes rise for end of pandemic as Pfizer says vaccine is 90% effective – The Guardian AND Four reasons for encouragement based on Pfizer’s Covid-19 vaccine results – STAT AND Expert reaction to Pfizer and BioNTech reporting interim results from phase 3 COVID-19 vaccine trial – Science Media Centre

 

Study shows preexisting cross-reactive antibodies against common cold coronaviruses may protect against SARS-CoV-2 and are more common in children

9 Nov, 2020 | 01:28h | UTC

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans – Science

Commentaries: Pre-existing coronavirus antibodies could help protect children against new pandemic strain – Francis Crick Institute AND Expert reaction to study looking at pre-existing coronavirus antibodies – Science Media Centre

 

Commentary on Twitter

 

Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. Efficacy, duration of protection, and percentage of the population receiving the vaccine are key issues

5 Nov, 2020 | 09:09h | UTC

Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination – The Lancet

 

Commentary on Twitter

 

Regeneron: Independent committee recommends holding trial enrollment in hospitalized patients with high oxygen requirements

2 Nov, 2020 | 02:31h | UTC

REGN-COV2 independent data monitoring committee recommends holding enrollment in hospitalized patients with high oxygen requirements and continuing enrollment in patients with low or no oxygen requirements – Regeneron

 

Commentary on Twitter

 

Scientists warn Americans are expecting too much from a vaccine

2 Nov, 2020 | 02:25h | UTC

Scientists Warn Americans Are Expecting Too Much From a Vaccine – Kaiser Health News

 

Randomized phase 2 trial: SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19

29 Oct, 2020 | 09:16h | UTC

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 – New England Journal of Medicine

Audio Interview: A New Monoclonal Antibody for Covid-19 – New England Journal of Medicine

 

Commentaries on Twitter

 

What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2

29 Oct, 2020 | 09:09h | UTC

What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2 – The Lancet Infectious Diseases

 

Commentary on Twitter

 

Stay Updated in Your Specialty

 

No spam, just news.